ValiRx Plc (LSE:VAL), through its wholly owned subsidiary Inaphaea BioLabs, has entered into an exclusive licensing agreement with Dominion Biotech Ltd for the PredictRx® platform—a personalized cancer screening service designed to enhance precision oncology. Under the terms of the agreement, Inaphaea will receive 50% of global net revenues generated from the platform, marking a strategic milestone that validates the commercial potential of ValiRx’s capabilities in translational science.
This deal represents a critical step in demonstrating the market value of ValiRx’s technology portfolio and establishing a potential buyout path, which could improve the company’s positioning within the precision medicine space. The agreement also strengthens Inaphaea’s service offerings and reinforces ValiRx’s role in bridging early-stage innovation with clinical application.
While ValiRx continues to face financial constraints—including ongoing profitability and cash flow challenges—its focus on strategic licensing and partnerships remains central to its growth trajectory. These collaborations are key drivers of long-term value creation, despite current valuation headwinds.
About ValiRx Plc
ValiRx is a UK-based life sciences company specializing in early-stage oncology and women’s health therapeutics. The company is dedicated to accelerating the translation of cutting-edge scientific discoveries into clinically viable treatments. Through its development framework, ValiRx identifies, incubates, and advances promising drug candidates from pre-clinical stages to investor-ready assets, working closely with academic and industry partners to bring new therapies to market.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Leave a Reply